| Literature DB >> 27503013 |
Sheng-Na Li1, Xin-Lin Zhang2, Guo-Long Cai3, Ruo-Wei Lin2, He Jiang2, Jian-Zhou Chen2, Biao Xu2, Wei Huang2.
Abstract
BACKGROUND: Current risk stratification of idiopathic dilated cardiomyopathy (IDC) lacks sufficient sensitivity and specificity. The objective of this study was to investigate the predictive role of frontal QRS-T angles in IDC.Entities:
Mesh:
Year: 2016 PMID: 27503013 PMCID: PMC4989419 DOI: 10.4103/0366-6999.187844
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Baseline characteristics stratified by QRS-T angle
| Items | All patients ( | QRS-T angle ≤90° ( | QRS-T angle >90° ( | Statistical value | |
|---|---|---|---|---|---|
| Age (years) | 63 ± 16 | 63 ± 18 | 64 ± 15 | −0.207* | 0.836 |
| Male | 338 (66) | 133 (69) | 205 (65) | 0.876† | 0.349 |
| Current smoker | 147 (29) | 52 (27) | 95 (30) | 0.568† | 0.467 |
| Diabetes mellitus | 116 (23) | 32 (17) | 84 (27) | 6.812† | 0.009 |
| Hypertension | 195 (38) | 77 (40) | 118 (37) | 0.331† | 0.565 |
| Atrial fibrillation | 150 (29) | 60 (31) | 90 (28) | 0.392† | 0.531 |
| Duration of CHF >1 (years) | 277 (54) | 88 (46) | 189 (60) | 9.760† | 0.002 |
| Clinical variables | |||||
| NYHA class ≥III | 360 (71) | 117 (61) | 243 (77) | 15.333† | <0.001 |
| Beta-blockers | 369 (72) | 152 (79) | 217 (69) | 6.112† | 0.013 |
| ACEI/ARB | 427 (84) | 173 (90) | 254 (80) | 7.598† | 0.006 |
| Loop diuretics | 434 (85) | 151 (78) | 283 (90) | 12.218† | <0.001 |
| Spironolactone | 370 (73) | 125 (65) | 245 (78) | 9.835† | 0.002 |
| Digoxin | 226 (44) | 87 (45) | 139 (44) | 0.058† | 0.810 |
| Aspirin | 186 (37) | 70 (36) | 116 (37) | 0.010† | 0.920 |
| Warfarin | 47 (9) | 25 (13) | 22 (7) | 5.132† | 0.023 |
| Amiodarone | 26 (5) | 12 (6) | 14 (4) | 0.790† | 0.374 |
| Systolic blood pressure (mmHg) | 125 ± 20 | 127 ± 18 | 125 ± 21 | 0.983* | 0.326 |
| Diastolic blood pressure (mmHg) | 78 ± 13 | 79 ± 13 | 78 ± 13 | 0.796* | 0.426 |
| Heart rate (beats/min) | 77 ± 22 | 76 ± 21 | 77 ± 23 | −0.510* | 0.610 |
| ICD | 56 (11) | 14 (7) | 42 (13) | 4.460† | 0.035 |
| ECG parameters | |||||
| PR interval (ms) | 181 ± 43 | 174 ± 40 | 185 ± 45 | −2.325* | 0.025 |
| QRS duration (ms) | 119 ± 31 | 109 ± 28 | 125 ± 32 | −5.273* | <0.001 |
| QT interval (ms) | 401 ± 54 | 392 ± 48 | 406 ± 56 | −2.867* | 0.004 |
| QTc (ms) | 438 ± 44 | 429 ± 37 | 443 ± 47 | −3.557* | <0.001 |
| P-wave axis (°) | 46 (30–61) | 46 (30–61) | 47 (30–61) | −0.028‡ | 0.978 |
| QRS axis (°) | 5 (−33 to 46) | 28.5 (−1.5 to 58.0) | −12 (−43 to 36) | –6.056‡ | <0.001 |
| T-wave axis (°) | 90 (47–150) | 59 (19–90) | 116 (90–166) | −9.792‡ | <0.001 |
| QRS-T angle (°) | 107 ± 54 | 45 ± 25 | 145 ± 25 | −42.165* | <0.001 |
| Any bundle branch block | 194 (38) | 49 (25) | 145 (46) | 21.343† | <0.001 |
| LBBB | 153 (30) | 32 (17) | 121 (38) | 33.250† | <0.001 |
| RBBB | 40 (8) | 17 (9) | 23 (7) | 0.387† | 0.534 |
| 24-h ECG recording | |||||
| PVC | 495 (38–2449) | 154 (14–2242) | 629 (79–2679) | −2.533‡ | 0.049 |
| NSVT | 3 (4–37) | 1 (0–19) | 4 (7–61) | −1.928‡ | 0.041 |
| Echocardiography | |||||
| LVEF (%) | 33 ± 8 | 36 ± 8 | 31 ± 7 | 6.643* | <0.001 |
| LVEDd (cm) | 6.7 ± 0.8 | 6.6 ± 0.8 | 6.8 ± 0.8 | −3.432* | 0.001 |
| LVEDs (cm) | 5.7 ± 1.9 | 5.7 ± 2.9 | 5.7 ± 0.9 | −0.299* | 0.765 |
| LAD (cm) | 4.90 (4.40–5.40) | 4.9 ± 0.8 | 5.00 (4.40–5.50) | −1.535‡ | 0.125 |
| Interventricular septum (cm) | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 1.0 | 0.341* | 0.733 |
| Posterior wall (cm) | 0.85 (0.80–0.94) | 0.90 ± 0.10 | 0.85 (0.79–0.95) | −0.456‡ | 0.648 |
| PAP (mmHg) | 48 ± 12 | 45 ± 13 | 49 ± 12 | −2.524* | 0.012 |
| Laboratory examination | |||||
| Creatinine (mg/L) | 800 (670–1000) | 790 (630–930) | 810 (680–1040) | −1.950‡ | 0.038 |
| Hemoglobin (10−4×mg/L) | 132 ± 22 | 133 ± 22 | 132 ± 22 | 0.211* | 0.833 |
| Sodium (mmol/L) | 142 ± 3 | 142 ± 3 | 142 ± 4 | 0.178* | 0.859 |
| BNP (10−6×mg/L) | 672 (312–1495) | 463 (156–1060) | 786 (406–1535) | −4.556‡ | <0.001 |
Data were presented as n (%), mean ± SD, or median (IQR). *t value; †χ2 value; ‡Z value. P values were from comparisons between patients with QRS-T angles ≤90°and >90°. CHF: Congestive heart failure; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; BNP: B-type natriuretic peptide; ICD: Implantable cardioverter-defibrillator; QTc: Corrected QT; LBBB: Left bundle branch block; RBBB: Right bundle branch block; PVC: Premature ventricular complexes; NSVT: Nonsustained ventricular tachycardia; LVEF: Left ventricular ejection fraction; LVEDd: Left ventricular end-diastolic diameter; LVEDs: Left ventricular end-systolic diameter; LAD: Left atrial diameter; PAP: Pulmonary arterial pressure; SD: Standard deviation; IQR: Interquartile range; 1 mmHg = 0.133 kPa.
Figure 1Kaplan-Meier curves for each endpoint according to frontal QRS-T angle. All-cause mortality (a), cardiac mortality (b), and heart failure rehospitalization (c) were presented, respectively. Survival curves were significantly different between QRS-T angle >90° and ≤90° for all endpoints.
Summary of outcome data regarding QRS-T angle
| Items | QRS-T angle ≤90° (%) | QRS-T angle >90° (%) | Adjusted | |
|---|---|---|---|---|
| All-cause mortality | 31/193 (16.1) | 90/316 (28.5) | 2.4 (1.5–3.6) | 2.5 (1.2–5.1) |
| Cardiac mortality | 25/193 (13.0) | 79/316 (25.0) | 2.4 (1.5–3.9) | 1.9 (1.0–3.5) |
| Heart failure rehospitalization | 41/193 (21.2) | 126/316 (39.9) | 2.5 (1.7–3.5) | 2.3 (1.3–4.2) |
Data were presented as n/N (%) or 95% CI. HR: Hazard ratio; CI: Confidence interval.
HRs for all-cause mortality in univariate analyses
| Items | |||
|---|---|---|---|
| QRS-T angle | 2.365 (1.542–3.628) | 0.861 | <0.001 |
| Age | 1.011 (1.003–1.019) | 0.029 | 0.009 |
| Gender | 1.439 (0.987–2.097) | 0.356 | 0.058 |
| Current smoker | 1.019 (0.684–1.516) | 0.367 | 0.927 |
| Diabetes mellitus | 1.471 (0.985–2.196) | 0.406 | 0.059 |
| Atrial fibrillation | 1.529 (1.063–2.199) | 0.544 | 0.221 |
| Heart rate | 0.996 (0.987–1.006) | −0.004 | 0.442 |
| NYHA | 1.872 (1.432–2.447) | 0.605 | <0.001 |
| Beta-blockers | 0.471 (0.325–0.681) | −0.776 | <0.001 |
| ACEI/ARB | 0.486 (0.317–0.744) | −0.825 | 0.001 |
| Loop diuretics | 1.417 (0.795–2.525) | 0.287 | 0.237 |
| Spironolactone | 1.239 (0.805–1.908) | 0.095 | 0.330 |
| Digoxin | 1.075 (0.745–1.550) | 0.348 | 0.701 |
| Aspirin | 0.858 (0.580–1.269) | −0.043 | 0.443 |
| Warfarin | 0.653 (0.304–1.403) | −0.053 | 0.275 |
| Amiodarone | 0.517 (0.190–1.404) | −0.337 | 0.196 |
| Systolic blood pressure | 0.991 (0.981–1.001) | −0.005 | 0.085 |
| Diastolic blood pressure | 0.986 (0.971–1.001) | −0.006 | 0.071 |
| PR interval | 1.005 (1.000–1.010) | 0.005 | 0.053 |
| QRS interval | 1.011 (1.006–1.017) | 0.011 | <0.001 |
| QTc | 1.005 (1.000–1.009) | 0.005 | 0.043 |
| P-wave axis | 0.999 (0.993–1.005) | −0.001 | 0.712 |
| QRS axis | 1.002 (0.998–1.005) | 0.002 | 0.331 |
| T-wave axis | 1.001 (0.998–1.003) | 0.000 | 0.557 |
| LBBB | 1.809 (1.244–2.631) | 0.615 | 0.002 |
| RBBB | 1.546 (1.047–2.926) | 0.670 | 0.053 |
| PVC | 1.000 (1.000–1.000) | 0.000 | 0.886 |
| NSVT | 1.001 (0.763–1.374) | −0.011 | 0.913 |
| LVEF | 0.967 (0.944–0.991) | −0.044 | 0.008 |
| LVEDd | 1.129 (0.892–1.430) | 0.162 | 0.039 |
| LAD | 1.040 (1.007–1.097) | −0.003 | 0.626 |
| BNP | 1.000 (1.000–1.001) | 0.000 | <0.001 |
| Creatinine | 1.006 (0.922–1.016) | −0.002 | 0.054 |
| Sodium | 0.904 (0.856–0.954) | 0.025 | 0.066 |
Variables with a P<0.05 were entered into the multivariable model. HR: Hazard ratio; CI: Confidence interval; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; QTc: Corrected QT; LBBB: Left bundle branch block; RBBB: Right bundle branch block; PVC: Premature ventricular complexes; NSVT: Nonsustained ventricular tachycardia; LVEF: Left ventricular ejection fraction; LVEDd: Left ventricular end-diastolic diameter; LAD: Left atrial diameter; BNP: B-type natriuretic peptide.
HRs for all endpoints in multivariable analyses
| Items | |||
|---|---|---|---|
| All-cause mortality | |||
| QRS-T angle | 2.453 (1.188–5.065) | 0.951 | 0.015 |
| NYHA | 1.780 (1.202–2.634) | 0.784 | 0.004 |
| Age | 1.013 (1.002–1.024) | 0.031 | 0.016 |
| QRS interval | 1.011 (1.003–1.019) | 0.017 | 0.008 |
| ACEI/ARB | 0.523 (0.299–0.915) | −0.607 | 0.023 |
| Cardiac mortality | |||
| QRS-T angle | 1.866 (1.004–3.468) | 1.024 | 0.049 |
| LBBB | 1.831 (1.126–2.976) | 0.687 | 0.015 |
| NYHA | 1.668 (1.108–2.510) | 0.508 | 0.014 |
| Age | 1.032 (1.013–1.052) | 0.032 | 0.001 |
| BNP | 1.000 (1.000–1.001) | 0.000 | 0.011 |
| Heart failure Rehospitalization | |||
| QRS-T angle | 2.321 (1.275–4.224) | 0.784 | 0.006 |
| BNP | 1.051 (1.013–1.079) | 0.000 | 0.008 |
P<0.05 indicates that this item is an independent predictor of the endpoint. HR: Hazard ratio; CI: Confidence interval; NYHA: New York Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; LBBB: Left bundle branch block; RBBB: Right bundle branch block; BNP: B-type natriuretic peptide.
Figure 2Kaplan-Meier curves for all-cause mortality stratified by gender. Significant difference was observed between QRS-T angle >90° and ≤90° in both men (a) and women (b) patients.